Wegovy

Adjunct to reduced-calorie diet & increased physical activity for wt management, including wt loss & wt maintenance, in adults w/ initial BMI of ≥30 kg/m² (obesity), or ≥27 kg/m²-<30 kg/m² (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia, obstructive sleep apnoea or CV disease; to reduce risk of major adverse CV events (CV death, non-fatal MI or stroke) in adults w/ established CV disease & either obese or overwt. Adjunct to reduced-calorie diet & increased physical activity for wt management in adolescents ≥12 yr w/ obesity & body wt >60 kg.

SC Adult & adolescent ≥12 yr Dose escalation schedule: Wk 1-4: 0.25 mg once wkly; wk 5-8: 0.5 mg once wkly; wk 9-12: 1 mg once wkly; wk 13-16: 1.7 mg once wkly. Maintenance dose: 2.4 mg once wkly.

May be taken with or without food: Take at any time of the day.

Hypersensitivity.

Not to be administered IV or IM. Pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing general anaesth or deep sedation. Advise patients of potential risk of dehydration in relation to GI side effects; rarely leads to deterioration of renal function. Avoid fluid depletion. Acute pancreatitis. Discontinue treatment if pancreatitis is suspected; do not restart if confirmed. Caution in patients w/ history of pancreatitis. Not a substitute for insulin in patients w/ type 2 diabetes. Do not use in combination w/ other GLP-1 receptor agonists. Increased risk of hypoglycaemia in combination w/ sulfonylurea or insulin; developing diabetic retinopathy complications in patients w/ diabetic retinopathy; residual gastric content prior to performing procedures w/ general anaesth or deep sedation. Closely monitor patients w/ diabetic retinopathy & treat according to clinical guidelines. Not recommended in patients w/ type 2 diabetes w/ uncontrolled or potentially unstable diabetic retinopathy; type 1 diabetes; CHF NYHA Class IV. Not recommended in patients treated w/ other products for wt management. Caution in patients w/ inflammatory bowel disease; diabetic gastroparesis. Avoid hypoglycaemia while driving & using machines when used in combination w/ sulfonylurea or insulin. Dizziness may occur which may affect ability to drive & use machines. Not recommended in patients w/ severe renal impairment (eGFR <30 mL/min/1.73 m²), including patients w/ ESRD; severe hepatic impairment. Mild or moderate hepatic impairment. Women of childbearing potential should use contraception during treatment. Do not use during pregnancy & breast-feeding. Discontinue treatment if pregnancy occurs; atleast 2 mth before planned pregnancy. Childn <12 yr. Elderly ≥85 yr.

Headache; vomiting, diarrhoea, constipation, nausea, abdominal pain; fatigue. Hypoglycaemia in patients w/ type 2 diabetes; dizziness, dysgeusia, dysaesthesia; diabetic retinopathy in patients w/ type 2 diabetes; gastritis, GERD, dyspepsia, eructation, flatulence, abdominal distension; cholelithiasis; hair loss; inj site reactions.

Delayed gastric emptying time & potential influence on absorption of concomitantly administered oral medicinal products. Decreased INR when used concomitantly w/ acenocoumarol. Frequent INR monitoring w/ warfarin or other coumarin derivatives.

Antidiabetic Agents

A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

K